MRK Merck & Company Inc. (new)

85.98
-2.58  -3%
Previous Close 88.56
Open 88.63
Price To Book 8.16
Market Cap 218,903,716,529
Shares 2,545,984,142
Volume 14,269,886
Short Ratio 3.42
Av. Daily Volume 8,186,627
Stock charts supplied by TradingView

NewsSee all news

  1. Koneksa Health Announces Study Publication Validating mHealth Technologies in Early-Stage Clinical Trial Safety Monitoring

    NEW YORK, Jan. 24, 2020 /PRNewswire/ -- Koneksa Health, the leader in developing and implementing patient-focused digital biomarkers for drug development, along with Merck & Co, Inc. (NYSE:MRK) announced the

  2. Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus

    Collaboration includes the National Institutes of Health (NIH) and leverages flexibility of Moderna's mRNA vaccine technology Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA

  3. Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)

    Approval Based on Results of KEYNOTE-426, Where KEYTRUDA® in Combination with Axitinib Reduced the Risk of Death by Nearly Half Compared to Sunitinib Renal cell carcinoma (RCC) is the most common form of kidney

  4. BriaCell Invited to Present at Mount Sinai's Frontiers in Academic Pathology Symposium at The New York Academy of Medicine

    BERKELEY, Calif., and VANCOUVER, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  5. FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

    Submission Based on PROfound, the First Phase 3 Trial Evaluating a Targeted Treatment in Biomarker-Selected Prostate Cancer Patients AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced February 19, 2019.
KEYTRUDA - EORTC1325/KEYNOTE-054
Melanoma
Approval announced June 13, 2018.
Keytruda
Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
FDA approval (label expansion) announced June 5, 2018.
KEYTRUDA + chemo (KEYNOTE-021)
First-Line Nonsquamous Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - July 24, 2017. Awarded accelerated approval in 2016.
KEYNOTE-040 KEYTRUDA
Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-183
Multiple myeloma
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-185
Multiple myeloma
Approved Sept. 22, 2017 under accelerated approval in patients undergoing third-line treatment following data from Phase 2 Keynote-59 trial. Phase 3 data released December 14, 2017 in patients undergoing second-line treatment, did not meet the primary endpoint of overall survival, nor did it show a significant improvement in PFS.
Keytruda
Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1/2 MOSAIC initiation of dosing announced October 2, 2019.
ARQ 092
Overgrowth Diseases
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
CRL issued April 7 2017. sNDA for approved drug requested to include data on cardiovascular effects
Januvia (Sitagliptin)
Type 2 Diabetes
Approved March 1, 2017.
Odactra (MK-8237)
House dust mite allergies
Approved May 18, 2017.
KEYTRUDA
First and Second line locally advanced or metastatic urothelial cancer - bladder cancer
FDA label expansion announced January 31, 2019.
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Approval announced December 20, 2017.
Ertugliflozin
Type 2 diabetes
Phase 3 interim analysis by DMC advised trial to be discontinued due to lack of benefit vs risk.
MK-8931 (019) - Verubecestat
Mild-to-moderate Alzheimer's
Approval announced November 9, 2017.
Letermovir
Cytomegalovirus (CMV) Infection
Phase 3 trial stopped due to lack of efficacy - February 14, 2017.
MK-8931 (017) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3 trial met its primary endpoint - October 2016. Updated data presented at ASCO 2017. HR 0.70. OS 10.3 months.
Keytruda - KEYNOTE-045
Bladder Cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Phase 3 planned.
Epacadostat with Keytruda -
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda -
Cancer - squamous cell carcinoma of the head and neck
Phase 3 data due released June 27, 2017. Primary endpoint met but noted August 29, 2017 that key secondary endpoint was not met. Announced October 11, 2017 that it will not seek regulatory approval.
Anacetrapib (MK-0859)
Raising HDL-C and reducing LDL-C
Approved May 10, 2017.
Keytruda
First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3 data due 2020.
MK-7264
Chronic cough
Approval announced March 14, 2017.
KEYTRUDA
Relapsed or Refractory Classical Hodgkin Lymphoma
PDUFA date March 8, 2017 extended to June 9, 2017 due to submission of extra data. Approved May 23, 2017.
KEYTRUDA
Microsatellite Instability-High Cancer
BLA acceptance announced May 23, 2016 by partner Samsung Bioepis. Approval annuonced April 21, 2017.
RENFLEXIS - SB2 (infliximab biosimilar)
Biosimilar candidate of Remicade
Approval announced May 30, 2017.
ISENTRESS
HIV-1
FDA Approval announced December 19, 2018.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Approval announced June 12, 2018.
KEYTRUDA
Cervical cancer
FDA Approval announced December 30, 2019.
Lynparza (POLO)
Pancreatic cancer
Phase 3 trial to be initiated 1H 2020.
Enfortumab vedotin and Keytruda
Urothelial cancer
FDA Approval announced April 11, 2019.
Keytruda - KEYNOTE-042
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Lynparza - OlympiA
HER2-negative breast cancer
FDA approval announced October 30, 2018.
KEYTRUDA + carboplatin-paclitaxel or nab-paclitaxel KEYNOTE-407
Squamous non-small cell lung cancer (sNSCLC)
Phase 1 presentation at ASH December 9, 2019. 89% ORR in CLL patients; 50% in Richter’s Transformation.
ARQ 531
B-cell malignancies
PDUFA date under priority review 2Q 2020.
Lynparza
Castration-Resistant Prostate Cancer
Approval announced October 5, 2018.
GARDASIL 9
Human Papilloma virus vaccine
Phase 1b trial ongoing.
ARQ 751
Solid tumors
PDUFA date under priority review 2Q 2020.
Lynparza + Avastin- PAOLA-1
First-line ovarian cancer
Phase 3 data released April 25, 2019 noted that monotherapy arm met noninferiority primary endpoint. Combo arm did not meet OS/PFS endpoints.
Keytruda KN-062
Gastric cancer
Phase 3 data February 19, 2019 did not meet primary endpoints.
Keytruda KN-240
Hepatocellular Carcinoma
Phase 3 data May 20, 2019 did not meet primary endpoint.
Keytruda KN-119
Triple negative breast cancer (TNBC)
FDA Approval announced June 11, 2019.
Keytruda KN-048
Head and neck squamous cell carcinoma (HNSCC)
Phase 3 data released July 29, 2019. Complete response endpoint met. Event-free survival (EFS) HR=0.63.
Keytruda KN-522
Triple negative breast cancer (TNBC)
FDA approval announced November 9, 2018.
Keytruda - KEYNOTE-224
Hepatocellular carcinoma (HCC)
FDA approval announced August 16, 2018.
LENVIMA (lenvatinib)
Hepatocellular Carcinoma (HCC)
FDA Approval announced December 19, 2018.
Keytruda KN-17
Merkel Cell Carcinoma
FDA approval announced June 3, 2019.
ZERBAXA(ceftolozane and tazobactam)
Hospital-acquired bacterial pneumonia (HABP)
Phase 1 data at ESMO October 2018 noted zero responses in monotherapy arm, 24% with Keytruda.
MK-1454 - STING
Solid tumors
FDA approval announced April 22, 2019.
KEYTRUDA and Inlyta - KEYNOTE-426
Renal cell carcinoma
Phase 3 trial met primary endpoint - November 18, 2019.
Vericiguat
Heart Failure
Phase 3 data due estimated 1H 2020.
Keytruda KN-355
Triple negative breast cancer (TNBC)
FDA Approval announced July 31, 2019.
Keytruda KN-181
Esophageal Cancer
Phase 3 data due 2020.
Keytruda KN-177
Colorectal cancer (CRC)
Phase 3 data due 2020.
Keytruda KN-361
Bladder cancer
Phase 3 data met PFS primary endpoint; overall survival primary endpoint not met - January 6, 2020.
Keytruda KN-604
Small cell lung cancer (SCLC)
Phase 3 data due 2020.
LENVIMA (lenvatinib) + Keytruda - KN-581
Renal cell carcinoma (RCC) - cancer
FDA Approval announced December 19, 2019.
ERVEBO (V920)
Ebola
FDA Approval for sNDA announced September 20, 2019.
DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate)
HIV
Phase 3 data due 2020.
Keytruda KN-122
Nasopharyngeal Carcinoma
FDA Approval announced July 17, 2019.
Imipenem/ cilastatin
Complicated urinary tract infections (cUTI) and Complicated intra-abdominal infections (cIAI)
FDA Approval announced June 18, 2019.
Keytruda - KN-158
Small cell lung cancer (SCLC)
Phase 3 trial planned.
MK-8591
HIV
PDUFA date February 18, 2020.
Keytruda
6-week dosing for melanoma and other indications
Phase 3 data presented at ESMO September 2019.
Pembrolizumab vs chemotherapy
Malignant pleural mesothelioma (MPM)
FDA Approval announced September 17, 2019.
Keytruda and Lenvima
Endometrial cancer
PDUFA date January 24, 2020
DIFICID (fidaxomicin)
Clostridium difficile infections (CDI)
FDA Approval announced January 8, 2020.
Keytruda KN-057
NMIBC Bladder cancer

Latest News

  1. Koneksa Health Announces Study Publication Validating mHealth Technologies in Early-Stage Clinical Trial Safety Monitoring

    NEW YORK, Jan. 24, 2020 /PRNewswire/ -- Koneksa Health, the leader in developing and implementing patient-focused digital biomarkers for drug development, along with Merck & Co, Inc. (NYSE:MRK) announced the

  2. Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus

    Collaboration includes the National Institutes of Health (NIH) and leverages flexibility of Moderna's mRNA vaccine technology Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA

  3. Health Canada Approves KEYTRUDA® (pembrolizumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)

    Approval Based on Results of KEYNOTE-426, Where KEYTRUDA® in Combination with Axitinib Reduced the Risk of Death by Nearly Half Compared to Sunitinib Renal cell carcinoma (RCC) is the most common form of kidney

  4. BriaCell Invited to Present at Mount Sinai's Frontiers in Academic Pathology Symposium at The New York Academy of Medicine

    BERKELEY, Calif., and VANCOUVER, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  5. FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

    Submission Based on PROfound, the First Phase 3 Trial Evaluating a Targeted Treatment in Biomarker-Selected Prostate Cancer Patients AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada,

  6. Significant Study on Veterinary Wellbeing Reveals Importance of Continued Focus on Personal and Professional Health and Wellbeing Among Veterinarians

    ORLANDO, Fla., Jan. 18, 2020 /PRNewswire/ -- Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the results of a comprehensive study of wellbeing and mental health

  7. Merck Completes Acquisition of ArQule

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of ArQule,

  8. FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as First-Line Maintenance with Bevacizumab in Advanced Ovarian Cancer and Grants Priority Review

     Submission Based on PAOLA-1 Trial Which Studied LYNPARZA with Bevacizumab in Women Regardless of Their Biomarker Status Who Responded to Platinum-Based Chemotherapy AstraZeneca and Merck (NYSE:MRK), known as MSD

  9. BriaCell Provides Update on Remarkable Responder

    Patient initially identified September 19, 2019

  10. Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area

    mRNA-6231 encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases mRNA-6981 encodes PD-L1 to treat autoimmune disease, initially to be

  11. BriaCell Outlines New High Responding Patient Group 'Biomarker' Based on Cancer Grade

    BriaCell has identified a patient population Biomarker with high rate of clinical benefit from the treatments based on ‘Breast Cancer Grade';Breast Cancer Grade correlates with response in bot

  12. FDA Approves Merck's KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Ineligible for or Have Elected Not to Undergo Cystectomy

    KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Certain Patients With High-Risk, Non-Muscle Invasive Bladder Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the

  13. Merck's KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cancer

    Phase 3 KEYNOTE-604 Study Did Not Meet Other Dual Primary Endpoint of Overall Survival; Results to be Presented at Upcoming Medical Meeting Merck (NYSE:MRK), known as MSD outside the

  14. Merck Establishes Strategic Oncology Collaboration with Taiho and Astex

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., ("Taiho") and Astex

  15. Merck to Hold Fourth-Quarter and Full-Year 2019 Sales and Earnings Conference Call on February 5

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on

  16. BriaCell Completes Share Consolidation

    BERKELEY, Calif., and VANCOUVER, British Columbia, Jan. 02, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  17. Merck to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories,

  18. LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

    LYNPARZA Reduced the Risk of Disease Progression or Death by 47% Compared to Placebo in Patients Whose Disease Had Not Progressed On at Least 16 Weeks of a First-Line Platinum-Based Chemotherapy Regimen Only PARP

  19. BriaCell Therapeutics Corp. Announces Share Consolidation

    BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 24, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  20. NewLink Genetics Announces FDA Approval of Ebola Vaccine V920 (ERVEBO®)

    AMES, Iowa, Dec. 20, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that, after priority review, the FDA has granted approval of ERVEBO®, or Zaire Ebola virus vaccine V920

  21. Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live)

    Action Represents Another Milestone for the Global Partnership Against Ebola Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has

  22. Merck's KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer

    KEYTRUDA Now Approved for Six Cancer Types Plus Microsatellite Instability-High (MSI-H) Tumors in Japan Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's

  23. FDA Oncologic Drugs Advisory Committee (ODAC) Recommends KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) voted 9-4 in favor of recommending

  24. Merck Animal Health Completes Acquisition of Vaki to Further Broaden Its Leadership Position in Aquaculture to Advance Fish Health and Welfare

    Strategic Transaction Benefits and Improves Aquaculture Health and Performance Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its

  25. LYNPARZA® (olaparib) Recommended by FDA Advisory Committee for First-Line Maintenance Therapy in Germline BRCA-Mutated Metastatic Pancreatic Cancer That Has Not Progressed on Platinum-Based Chemotherapy

    Oncologic Drugs Advisory Committee Voted That LYNPARZA Demonstrated a Favorable Benefit-Risk Profile for Patients Based on Phase 3 POLO Trial Results AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United

  26. Merck Begins Tender Offer to Acquire ArQule

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of ArQule, Inc. (NASDAQ:ARQL). On

  27. BriaCell to Present at Biotech Showcase™ 2020 in San Francisco

    BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 17, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  28. BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®

    Safety and early efficacy data were presented on December 12th at 6:00 p.m. ET from the clinical trials of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer:

  29. Moderna Announces Key 2020 Investor and Analyst Events

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its key

  30. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  31. Merck to Acquire ArQule, Advancing Leadership in Oncology

    Acquisition Further Diversifies Merck's Oncology Pipeline with Expansion into Targeted Therapies That Treat Hematological Malignancies Merck (NYSE:MRK), known as MSD outside the United States and Canada, and ArQule,

  32. LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer

    AstraZeneca and Merck's LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Versus Placebo in BRCAm Advanced Ovarian Cancer Following Response to Platinum-Based Chemotherapy Only PARP Inhibitor Approved

  33. Merck to Present at the Evercore ISI HealthCONx Conference 2019

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Michael Nally, chief marketing officer for Merck is scheduled to present during a fireside chat at the Evercore ISI HealthCONx

  34. FDA Grants Priority Review to Merck's Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)

    Application Based on Results from Phase 2 KEYNOTE-057 Trial, to be Discussed at December FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Merck (NYSE:MRK), known as MSD outside the United States and Canada, today

  35. Merck's KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy

    Third Approval for KEYTRUDA in First-Line NSCLC in China in Less Than One Year Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been

  36. New Survey of Young Adults Uncovers Low Levels of Accurate Knowledge About HIV Transmission Coupled with High-Risk Sexual Behaviors

    KENILWORTH, N.J. and NEW YORK, Nov. 25, 2019 /PRNewswire/ -- Merck (NYSE:MRK) known as MSD outside the United States and Canada, in partnership with Prevention Access Campaign today launched Owning HIV: Young Adults and

  37. European Commission Approves Two New Regimens of Merck's KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

    KEYTRUDA is the First Anti-PD-1 Therapy Approved in Europe for the First-Line Treatment of Head and Neck Cancer as Monotherapy or in Combination with Chemotherapy, in Patients Whose Tumors Express PD-L1 (CPS

  38. Merck Announces First-Quarter 2020 Dividend

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.61 per share of the company's common stock for the first quarter

  39. Ontario and Quebec provide reimbursement for HIV therapies PIFELTRO® (doravirine) and DELSTRIGO® (doravirine/lamivudine/tenofovir disoproxil fumarate)

    Although treatment progress has been made, human immunodeficiency virus (HIV) is still one of the world's most serious public health challenges.i In 2018, approximately 37.9 million people were living with HIV

  40. Merck and Bayer's Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure

    Vericiguat Reduced the Risk of Heart Failure Hospitalization or Cardiovascular Death in Patients with Worsening Chronic Heart Failure with Reduced Ejection Fraction, Compared to Placebo When Added to Available Heart

  41. BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration

    Extended Duration Formulation Ensures Cats Receive Broad-Spectrum Parasite Coverage in One Topical Application Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced

  42. US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review

    AstraZeneca and Merck's Selumetinib Would Become the First Medicine Indicated for the Treatment of Certain Pediatric Patients with NF1 Plexiform Neurofibromas if Approved AstraZeneca and Merck (NYSE:MRK), known as MSD

  43. NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO®)

    AMES, Iowa, Nov. 12, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that Monday, November 11th, the European Commission (EC) granted a conditional marketing authorization to ERVEBO®,

  44. BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th

    Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer:

  45. Merck's ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union

     Authorization Represents Significant Advancement in the Global Response to Ebola Merck Remains Committed to Working with International Health Partners in Ebola Outbreak Response Merck (NYSE:MRK), known as MSD

  46. NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    AMES, Iowa, Nov. 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the third quarter ended September 30, 2019 and provided an update on corporate activities.

  47. Merck Announces Third-Quarter 2019 Financial Results

    Third-Quarter 2019 Worldwide Sales Were $12.4 Billion, an Increase of 15%; Sales Increased 16% Excluding Impact from Foreign Exchange; Growth Driven by Oncology and Human Health Vaccines KEYTRUDA Sales Grew 62% to

  48. BriaCell Announces Voting Results of the Special Meeting of Shareholders

    BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  49. NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)

    AMES, Iowa, Oct. 21, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use

  50. NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)

    AMES, Iowa, Oct. 21, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use

  51. NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)

    AMES, Iowa, Oct. 21, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use

  52. NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)

    AMES, Iowa, Oct. 21, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use

  53. Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

    Opinion Supports Use of KEYTRUDA, as Monotherapy or in Combination with Platinum and 5-Fluorouracil Chemotherapy, in Patients Whose Tumors Express PD-L (CPS ≥1) Merck (NYSE:MRK), known as MSD outside the United States

  54. Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion

  55. NexTech Appoints New Chief Financial Officer

    NEW YORK and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- NexTech AR Solutions (the "Company" or "NexTech") (OTCQB:NEXCF) (CSE:NTAR) (FSE: N29) is pleased to announce that it has appointed Kashif Malik as Chief Financial

  56. BriaCell Therapeutics Corp. to File Amendment to Management Information Circular

    BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  57. Merck Issues 2018/2019 Corporate Responsibility Report

    Report Illustrates Merck's Approach to Long-Term Sustainability for Business and Society Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued its 2018/2019 Corporate Responsibility Report.

  58. BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer

    Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell's lead candidate, Bria-IMT™ in combination with Incyte's INCMGA00012 and epacadostat in patients with advanced breast cancer.Cancer blocks the immune system pr

  59. Merck's KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

    KEYTRUDA is First Anti-PD-1 Therapy Approved as Monotherapy and in Combination with Chemotherapy in First-Line Setting for NSCLC in China Merck (NYSE:MRK), known as MSD outside the United States and Canada, today

  60. FDA Accepts Two Applications for Merck's DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections

    DIFICID® Pediatric Filings Receive Priority Review Classification Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for

  61. BriaCell Therapeutics Corp. to Clarify Record Date

    BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  62. Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 29.

  63. Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month

    BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  64. Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

    TOKYO, Oct 1, 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A.

  65. LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months)

    Merck and AstraZeneca's LYNPARZA Reduced the Risk of Disease Progression or Death by 51% in Men with Homologous Recombination Repair (HRR) Gene Mutations First Positive Phase 3 Trial Evaluating a Targeted Treatment in

  66. Companies Seek an Innovative Solution to the Growing Cancer Rates

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World Cancer Research Fund (WCRF)

  67. Merck to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Michael Nally, Chief Marketing Officer for Merck, is scheduled to present during a fireside chat at the Cantor Fitzgerald 2019

  68. Pivotal RESTORE-IMI 2 Phase 3 Study of Merck's RECARBRIO™ (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 RECARBRIO™ (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) RESTORE-IMI 2 trial met its primary

  69. Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)

    Interim Results from Pivotal Neoadjuvant/Adjuvant Phase 3 KEYNOTE-522 Trial Presented for the First Time at ESMO 2019 Congress During Presidential Symposium As Previously Announced, KEYTRUDA Plus Chemotherapy Has Been

  70. Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Eisai today announced final results from the full endometrial cancer cohort of KEYNOTE-146/Study 111 evaluating KEYTRUDA, Merck's anti-PD-1

  71. LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer

    AstraZeneca and Merck's LYNPARZA Added to Bevacizumab Reduced the Risk of Disease Progression or Death by 41% in the Overall Trial Population of Women Who Responded to Platinum-Based Chemotherapy AstraZeneca and Merck

  72. BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special 'Targeted Immunotherapy' Issue in Prestigious Journals

    BERKELEY, Calif., and VANCOUVER, British Columbia, Sept. 25, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  73. BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®

    Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress.  Publicly-traded securities of BriaCell Therapeutics Corp.

  74. Biotech Companies Endeavor to Address Global Health Issues

    NEW YORK, Sept. 18, 2019 /PRNewswire/ -- The global burden of diseases continues to grow each year, despite ongoing medical advancements. The Institute for Health Metrics and Evaluation (IHME) highlighted in a report

  75. FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

    Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Who Have Disease Progression Following Prior Systemic Therapy and Are Not Candidates for Curative Surgery or Ra

  76. FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

    Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR), Who Have Disease Progression Following Prior

  77. FDA Accepts Merck's Biologics License Application (BLA) and Grants Priority Review for V920, the Company's Investigational Vaccine for Ebola Zaire Virus

    Merck Continues to Expand Investigational Supply to Support International Ebola Outbreak Response Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration

  78. Merck Announces First Nine "Safer Childbirth Cities" Committed to Reducing Maternal Deaths and Narrowing Disparities in the US

    Co-Funders Join Merck for Mothers to Support Newly Formed City-Based Coalitions Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today its funding support of projects in nine cities

  79. Pooled Analysis Continues to Show Merck's KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Advanced NSCLC Whose Tumors Do Not Express PD-L1

    Findings from Pooled Analysis of KEYNOTE-189, KEYNOTE-407 and KEYNOTE-021 (Cohort G) Presented at the IASLC 2019 World Conference on Lung Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada,

  80. Pivotal New Data from Merck's Broad Oncology Portfolio at ESMO 2019 Congress

    Phase 3 Data for KEYTRUDA® (pembrolizumab) as Neoadjuvant Therapy in Combination with Chemotherapy in Patients with Triple-Negative Breast Cancer (KEYNOTE-522) to be Featured in ESMO Presidential Symposium and Official

  81. Merck to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories,

  82. Merck Foundation Launches Five-Year Initiative to Reduce Disparities in HIV Care for Vulnerable and Underserved Southeastern US Communities

    The Merck Foundation (the Foundation) has launched HIV Care Connect, a $7 million, five-year initiative to help reduce disparities in access to care and improve health outcomes for persons with HIV living in vulnerable

  83. European Commission Approves Merck's KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)

    European Approval Based on KEYNOTE-426 Trial Results Demonstrating Significant Improvement in Overall Survival with KEYTRUDA in Combination with Axitinib Compared to Sunitinib KEYTRUDA is First Anti-PD-1 Therapy

  84. Merck Highlights New Data from Leading Lung Cancer Clinical Development Program at the IASLC 2019 World Conference on Lung Cancer

    Pooled Overall Survival (OS) Data from Three Trials with KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Subgroup of Patients with Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Do Not Express PD-L1 New KEYTRUDA